Chimeric Antigen Receptor (Car) T Cell Immunotherapy- Competitive Landscape

Summary

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015” emphasizes on the currently active CAR-T cell products in research and development. The Report covers the 35+ companies which are active in this field including 14 leading companies with 35 products targeting 20 different antigens and 9 different technologies. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

Report Highlights:

• CAR-T cell Therapy Pipeline scenario

• Collaborations & partnering deals

• Current Prominent Research Areas and Key Players

• Pipeline product profiles CAR-T Technologies and Targeted Antigens

• Licensing opportunities

• Market Drivers and Barriers

ACCESS REPORT:http://www.gosreports.com/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2015/

Scope

• Overview of the global CAR-T cell therapy pipeline scenario, products and associated companies information

• Coverage of global CAR-T cell therapies under development

• Competitive landscape of products for key players and related indications

• Coverage of licensors, collaborators and Development partners, deal terms and deal values estimation

• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities

• Highlights of licensing & collaboration opportunities and funding details...